Table 4 Subgroup analysis of EGFR and ALK mutant patients regarding iPFS and mOS and associated variables.
iPFS (months) | p | mOS (months) | p | |
|---|---|---|---|---|
EGFR mutant patients | ||||
Number of BM | ||||
1–3 | 22.7 (19.2–26.2) | < 0.001 | 29.6 (26–33.2) | < 0.001 |
≥ 4 | 9.7 (7.5–11.9) | 14 (10.5–17.5) | ||
Size of BM | ||||
< 3 cm | 17.7 (12.9–22.5) | 0.35 | 27.2 (22.8–31.5) | 0.78 |
≥ 3 cm | 10.7 (4.3–17.2) | 16.2 (3.7–28.7) | ||
Presence of extracranial metastases | ||||
No | 27.1 (13.2–41) | 0.03 | 24.9 (11.1–38.7) | 0.59 |
Yes | 16.4 (12.6–20.2) | 26.5 (22.9–30.1) | ||
ALK mutant patients | ||||
Number of BM | ||||
1–3 | 37.2 (23.9–50.6) | 0.002 | 61.7 (NE-NE) | 0.004 |
≥ 4 | 14.4 (3.9–24.9) | 33.2 (21.8–44.6) | ||
Size of BM | ||||
< 3 cm | 23.4 (16.1–30.8) | 0.65 | 44.3 (31.7–57) | 0.58 |
≥ 3 cm | 52.5 (1.8–103.3) | 61.7 (0.1–140.1) | ||
Presence of extracranial metastases | ||||
No | 87.16 (NE-NE) | 0.001 | NE | 0.008 |
Yes | 19.15 (10.7–27.6) | NE | ||
